These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 14965807)
1. Immunosuppression induction with daclizumab and antithymocyte globulin in cardiac transplantation: clinical experience with 8 cases. Huang XS; Chen DZ; Chen LW; Li ZQ; Liao CX Di Yi Jun Yi Da Xue Xue Bao; 2004 Feb; 24(2):126-8. PubMed ID: 14965807 [TBL] [Abstract][Full Text] [Related]
2. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. Carlsen J; Johansen M; Boesgaard S; Andersen CB; Arendrup H; Aldershvilet J; Mortensen SA J Heart Lung Transplant; 2005 Mar; 24(3):296-302. PubMed ID: 15737756 [TBL] [Abstract][Full Text] [Related]
4. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. Beniaminovitz A; Itescu S; Lietz K; Donovan M; Burke EM; Groff BD; Edwards N; Mancini DM N Engl J Med; 2000 Mar; 342(9):613-9. PubMed ID: 10699160 [TBL] [Abstract][Full Text] [Related]
5. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation. Cuppoletti A; Perez-Villa F; Vallejos I; Roig E Transplant Proc; 2005 Nov; 37(9):4036-8. PubMed ID: 16386620 [TBL] [Abstract][Full Text] [Related]
6. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation. Ailawadi G; Smith PW; Oka T; Wang H; Kozower BD; Daniel TM; Kron IL; Jones DR J Thorac Cardiovasc Surg; 2008 Mar; 135(3):594-602. PubMed ID: 18329476 [TBL] [Abstract][Full Text] [Related]
7. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation. Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480 [TBL] [Abstract][Full Text] [Related]
8. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3. Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282 [TBL] [Abstract][Full Text] [Related]
9. Single-shot antithymocyte globuline and daclizumab induction in simultaneous pancreas and kidney transplant recipient: three-year results. Schulz T; Flecken M; Kapischke M; Busing M Transplant Proc; 2005 May; 37(4):1818-20. PubMed ID: 15919476 [TBL] [Abstract][Full Text] [Related]
10. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. Burton CM; Andersen CB; Jensen AS; Iversen M; Milman N; Boesgaard S; Arendrup H; Eliasen K; Carlsen J J Heart Lung Transplant; 2006 Jun; 25(6):638-47. PubMed ID: 16730569 [TBL] [Abstract][Full Text] [Related]
14. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Kobashigawa J; David K; Morris J; Chu AH; Steffen BJ; Gotz VP; Gordon RD Transplant Proc; 2005 Mar; 37(2):1333-9. PubMed ID: 15848713 [TBL] [Abstract][Full Text] [Related]
15. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience. Ji SM; Li LS; Cheng Z; Cheng DR; Sun QQ; Chen JS; Sha GZ; Liu ZH Transplant Proc; 2007 Jun; 39(5):1396-401. PubMed ID: 17580147 [TBL] [Abstract][Full Text] [Related]
16. Neoquadruple induction with antithymocyte globulin/azathioprine/cyclosporine/prednisolone in simultaneous pancreas and kidney transplant recipients: 8.5-year results. Schulz T; Kapischke M; Busing M Transplant Proc; 2005 May; 37(4):1815-7. PubMed ID: 15919475 [TBL] [Abstract][Full Text] [Related]
17. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients? Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256 [TBL] [Abstract][Full Text] [Related]
18. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. Morris JA; Hanson JE; Steffen BJ; Chu AH; Chi-Burris KS; Gotz VP; Gordon RD Clin Transplant; 2005 Jun; 19(3):340-5. PubMed ID: 15877795 [TBL] [Abstract][Full Text] [Related]
19. Prevention of acute rejection with antithymocyte globulin (Thymoglobuline): its potential to reduce corticosteroids. Cantarovich D J Nephrol; 2004; 17 Suppl 8():S40-6. PubMed ID: 15599885 [TBL] [Abstract][Full Text] [Related]